Development of efficient on-bead protein elution process coupled to ultra-high performance liquid chromatography–tandem mass spectrometry to determine immunoglobulin G subclass and glycosylation for discovery of bio-signatures in pancreatic disease

Shiao, Jing-Ya; Chang, Yu-Ting; Chang, Ming‐Chu; Chen, Michael X.; Liu, Liwei; Wang, Xiangyu; Tsai, Yun-Jung; Kuo, Tai-Chih; Tsai, I‐Lin

doi:10.1016/j.chroma.2020.461039

Cited by 10 publications

(12 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In those studies, LC coupled with MS was usually the main analytical tool. In our previous work, we also developed and validated a UHPLC-MS/MS method to achieve absolute quantification of the four IgG subclasses, and relative quantification of 26 IgG glycopeptides, from plasma samples [ 18 ]. In this study, we applied the same workflow, to which a stable isotope-labeled IgG internal standard was added to each sample.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Mass Spectrometry Discovered Human IgG Sialylation as a Potential Biosignature for Kidney Function

Kao

Wang

Chuang

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

Immunoglobulin G (IgG) N-glycosylation was discovered to have an association with inflammation status, which has the potential to be a novel biomarker for kidney diseases. In this study, we applied an ultra-high performance liquid chromatography–tandem mass spectrometry (UHPLC-MS/MS) method to plasma and urine samples from 57 individuals with different levels of kidney function. Natural abundances of total IgG, IgG1, IgG2, and IgG3 subclasses in plasma showed positive correlations to the estimated glomerular filtration rates (eGFRs). Eighteen IgG glycopeptides also showed positive correlations. In contrast, higher IgG amounts were found in urine samples from participants with lower eGFR values. After normalizing IgG glycopeptides from plasma to their respective protein amounts, H4N4F1S1-IgG1 (r = 0.37, p = 0.0047, significant) and H5N4F1S1-IgG1 (r = 0.25, p = 0.063, marginally significant) were the two glycopeptides that still had positive correlations with eGFRs. The results showed that the UHPLC-MS/MS method is capable of investigating IgG profiles, and monitoring IgG and glycosylation patterns is worthy of further clinical application for kidney disease.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Sample preparation and analytical conditions were previously developed and validated by our team [ 18 ]. Briefly, 60 μL of magnetic bead slurry immobilized with protein G was used for IgG purification.…”

Section: Methodsmentioning

confidence: 99%

Clinical Mass Spectrometry Discovered Human IgG Sialylation as a Potential Biosignature for Kidney Function

Kao

Wang

Chuang

et al. 2021

JPM

Self Cite

View full text Add to dashboard Cite

show abstract

“…These studies have investigated glycation of human serum albumin (HSA) as markers for diabetes to complement HbA1c (Korwar et al, 2015). Glycosylation of immunoglobulin G (IgG), the most abundant antibody in serum, has further been investigated as a source of markers for pancreatic cancer and pancreatitis (Chen et al, 2014;Shih et al, 2019;Shiao et al, 2020). The focus on IgG is also consistent with the immune facets of both pancreatic cancer and T1D.…”

Section: Clinical Utility Considerationsmentioning

confidence: 99%

“…For multiple reaction monitoring assays requiring high sensitivity and quantitative accuracy, triple quadrupole instruments have become a common feature of clinical laboratories (Shiao et al, 2020). Instruments with other mass analyzers can perform the similarly named parallel reaction monitoring which can also enable fast and sensitive quantification.…”

Section: Clinical Utility Considerationsmentioning

confidence: 99%

“…A unique feature of this study is the incorporation of isotopically-labeled IgG as an internal standard to improve quantitative accuracy. Quantification was performed on serum using multiple reaction monitoring on a triple quadrupole mass spectrometer, identifying 7 IGPs for differentiating PDAC from autoimmune pancreatitis (Shiao et al, 2020).…”

Section: Differentiation Of Pancreatic Cancer From Pancreatitismentioning

confidence: 99%

See 1 more Smart Citation

Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases

Tabang

Ford

2021

Front. Chem.

View full text Add to dashboard Cite

Modification of proteins by glycans plays a crucial role in mediating biological functions in both healthy and diseased states. Mass spectrometry (MS) has emerged as the most powerful tool for glycomic and glycoproteomic analyses advancing knowledge of many diseases. Such diseases include those of the pancreas which affect millions of people each year. In this review, recent advances in pancreatic disease research facilitated by MS-based glycomic and glycoproteomic studies will be examined with a focus on diabetes and pancreatic cancer. The last decade, and especially the last five years, has witnessed developments in both discovering new glycan or glycoprotein biomarkers and analyzing the links between glycans and disease pathology through MS-based studies. The strength of MS lies in the specificity and sensitivity of liquid chromatography-electrospray ionization MS for measuring a wide range of biomolecules from limited sample amounts from many sample types, greatly enhancing and accelerating the biomarker discovery process. Furthermore, imaging MS of glycans enabled by matrix-assisted laser desorption/ionization has proven useful in complementing histology and immunohistochemistry to monitor pancreatic disease progression. Advances in biological understanding and analytical techniques, as well as challenges and future directions for the field, will be discussed.

show abstract

Response to Viewpoint by Bernhardt et al.

Kluge,

Schaeffer,

Berg

2024

Movement Disorders

View full text Add to dashboard Cite

Development of efficient on-bead protein elution process coupled to ultra-high performance liquid chromatography–tandem mass spectrometry to determine immunoglobulin G subclass and glycosylation for discovery of bio-signatures in pancreatic disease

Cited by 10 publications

References 32 publications

Clinical Mass Spectrometry Discovered Human IgG Sialylation as a Potential Biosignature for Kidney Function

Clinical Mass Spectrometry Discovered Human IgG Sialylation as a Potential Biosignature for Kidney Function

Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases

Response to Viewpoint by Bernhardt et al.

Contact Info

Product

Resources

About